Drug
EF-5 clinical trials
Also written EF5.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 1998
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 1 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 3
- Phase 2
- 4
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 11
National Cancer Institute (NCI) (6) · Duke University (1) · David M. Brizel, MD (1) · Gynecologic Oncology Group (1) · University Health Network, Toronto (1) · Mark Dewhirst (1)
Often tested with
Tested in the same studies.
Motexafin lutetium (1)
Studies
Open first, then newest update. How each study uses EF-5 is read from its arms, and is right about nine times in ten.
Testing it · 11
- EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue SarcomaTerminatedPhase 1University Health Network, TorontoNCT00004261Written as EF5
- EF5 in Assessing Tumor Response to Anticancer Therapy in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung CancerCompletedPhase 2Duke UniversityNCT00041028Written as EF5
- EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung CancerCompletedPhase 2National Cancer Institute (NCI)NCT02154399Written as EF5
- EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck CancerCompletedPhase 2David M. Brizel, MDNCT00049140Written as EF5
- EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical CancerCompletedNot applicableGynecologic Oncology GroupNCT00049231Written as EF5
- EF5 in Treating Patients With Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT00003282Written as EF5
- EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial CancerCompletedPhase 2National Cancer Institute (NCI)NCT00107445Written as EF5
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNot applicableNational Cancer Institute (NCI)NCT00087191Written as EF5
- Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedPhase 1National Cancer Institute (NCI)NCT00110032Written as EF5
- EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth CancerTerminatedNot applicableNational Cancer Institute (NCI)NCT00896961Written as EF5
- To Evaluate the Characteristics of a Breast CancerWithdrawnEarly Phase 1Mark DewhirstNCT01055678Written as EF5
Given in every arm · 1 — EF-5 is usual care beside what is tested
Codes
What other systems call EF-5 · ClinicalTrials.gg INT003871
- MeSH (NLM) C0960112-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamideConfirmed NLM, Wikidata
- UNII (FDA) 383HJ2T87OEF-5Confirmed FDA, NLM, Wikidata
- Wikidata Q5322954EF-5Confirmed FDA, NLM, Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C096011 | 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide | Confirmed NLM, Wikidata |
| UNII (FDA) | 383HJ2T87O | EF-5 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5322954 | EF-5 | Confirmed FDA, NLM, Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.